2026-06-30T02:00:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/155382024-11-29T14:25:57Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc García-Silva, Susana author Vico-Alonso, Cristina author Meyer, Lisa author Enderle, Daniel author Sanchez, J Aquiles author Onteniente, María Del Mar author Noerholm, Mikkel author Skog, Johan author Rodríguez-Peralto, José-Luis author Ortiz-Romero, Pablo-Luis author Peinado Selgas, Hector author 2023-02-15 To the editor, cutaneous melanoma in its early stages is a curable disease by surgery of skin lesions. However, intermediate stages display variable outcomes. BRAF V600 mutations are the most frequent alterations in melanoma ocurring in 35-50% of patients ( Luke et al., 2017) and remain informative for guiding first-line treatment election ( Robert et al., 2019). J Invest Dermatol. 2023 Feb 15;S0022-202X(23)00091-X. 10.1016/j.jid.2023.01.025 1523-1747 The Journal of investigative dermatology 36804405 http://hdl.handle.net/20.500.12105/15538 BRAF Melanoma Biomarkers Oncology Tumors markers Cancer Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.